Zovirax (Acyclovir)
Brand Names: Zovirax
Methodology & AI Transparency ⓘ
Zovirax (Acyclovir) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a proprietary herpes simplex virus nucleoside analog dna polymerase inhibitor presentation registered by Bausch Health US, LLC, Zovirax supplies active moiety Acyclovir (cross-referenced at /meds/acyclovir) in 50 mg/g Cream; 50 mg/g Ointment (NDC 0187-0994, 0187-0993; SPL 2024-12-31).
- 2 Real-world patient consensus: Registered under RxNorm 307730-B01870994 and SPL 2024-12-31, pairing Zovirax packaging with active ingredient Acyclovir.
- 3 Typical cash cost range: Dispensing cost comparison spans $6.30 mail/discount cash up to $34.50 uninsured retail (federal NADAC $0.1070).
- 4 Top reported side effects / signs: Most commonly reported Zovirax (Acyclovir) tolerability events: nausea (10.8%), vomiting (2.7%), headache (6.7%).
Ask our AI Specialists anything about Zovirax (Acyclovir)
Zovirax (Acyclovir) Mechanism, CYP450 Pathways & DailyMed Monograph
As a proprietary herpes simplex virus nucleoside analog dna polymerase inhibitor presentation registered by Bausch Health US, LLC, Zovirax supplies active moiety Acyclovir (cross-referenced at /meds/acyclovir) in 50 mg/g Cream; 50 mg/g Ointment (NDC 0187-0994, 0187-0993; SPL 2024-12-31). Clinical prescribing and dispensing guidelines focus on Herpes Zoster Infections: Acyclovir tablets, USP are indicated for the acute treatment of herpes zoster (shingles).
The active constituent inside Zovirax—Acyclovir—functions as a targeted herpes simplex virus nucleoside analog dna polymerase inhibitor agent with class-characteristic hepatorenal disposition. While therapeutic target engagement mirrors generic Acyclovir, Zovirax (registered by Bausch Health US, LLC, SPL 2024-12-31) specifies proprietary packaging (0187-0994, 0187-0993) and 50 mg/g Cream; 50 mg/g Ointment quality controls alongside a $0.1070/unit NADAC acquisition baseline.
Following administration (50 mg/g Cream), Zovirax (Acyclovir) achieves < 5% transdermal or mucosal systemic uptake from Zovirax (Acyclovir) bioavailability and initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (zovirax (acyclovir)) onset, governed by a Localized tissue retention for Zovirax (Acyclovir) with minimal systemic plasma half-life terminal half-life through local esterase/enzymatic cleavage of zovirax (acyclovir) with minimal hepatic cytochrome burden.
Before initiating Zovirax (Acyclovir) at 50 mg/g Cream, clinical safety checklists rule out documented intolerance or hypersensitivity reaction involving acyclovir (herpes simplex virus nucleoside analog dna polymerase inhibitor); concurrent restricted medications flagged in section 4/7 of the zovirax (acyclovir) dailymed monograph (307730-b01870994). Logged tolerability patterns center on nausea (10.8% of reports), headache (6.7% of reports), dizziness (6% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Zovirax (Acyclovir) (herpes simplex virus nucleoside analog dna polymerase inhibitor).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Zovirax (Acyclovir) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Acyclovir (herpes simplex virus nucleoside analog dna polymerase inhibitor)
- Concurrent restricted medications flagged in Section 4/7 of the Zovirax (Acyclovir) DailyMed monograph (307730-B01870994)
Logged Side-Effect Incidence (13 Reports)
Zovirax (Acyclovir) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Zovirax (Acyclovir))
Human clinical trial evidence for Zovirax (Acyclovir) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Zovirax (Acyclovir) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1070/unit (~$3.21/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $6.30 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 13 Anonymous DotMD Community Micro-Logs | $7.50 / mo | View logs ↓ |
Zovirax (Acyclovir) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Zovirax (Acyclovir) RxNorm Concept ID | 307730-B01870994 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1070 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $6.30 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 77.00% Worth It (13 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Zovirax (Acyclovir) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Zovirax (Acyclovir) (herpes simplex virus nucleoside analog dna polymerase inhibitor) monograph synthesizing RxNorm 307730-B01870994, openFDA FAERS signals, and $6.30–$34.50 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Zovirax (Acyclovir) community threads and patient logs by age, biological sex, dosage, and treatment duration.